RZLT Rezolute Inc

$RZLT I see the bots are starting to show up. That tells me we are in good shape moving forward!!

$RZLT Do the math... Tumor HI has a 98% chance of Statistical Significance since 7 of 8 patients have already hit the objective... 8 patients left to assess. FDA said 8 patients have to hit primary end pount to get approval... And with todays PreBLA press release... the FDA has "Encourged" RZLT to pursue this path

$RZLT even though these bears and hedge funds posing as Bears are insufferable, it means we are 9n the right track biy, hold, get rich.

$RZLT Big Update Today! Uplift Tumor-HI is now 7 for 8 responders (87.5%). The study needs 9 of 16 responders to meet statistical significance, RZLT needs only 2 responders from the next 8 patients. Six responders have also completely discontinued IV glucose. Tumor HI continues to look increasingly de-risked. Now waiting on FDA path forward for CHI.

$RZLT sucks this is giving back nearly all the gains from the pre-BLA meeting news, but upLIFT phase 3 results could hit any day now. 🤞

$RZLT If your bullish thesis is "bears are annoying, therefore buy and get rich", you’ve replaced analysis with a motivational poster 😏

$RZLT Those that have been here from the beginning, over the next several weeks and as we get closer to data readout this platform will start to have an increase of negativity towards this stock and will try to get you to sell your shares. Due your own due diligence because shorts are getting nervous with the recent news released today. I'm excited to see where the price will go!!

$RZLT looks like we have a Newbie Bear... welcome . Please entertain us with your estute onservations after the Cantor overweight rating.

$RZLT I don’t think people understand, this is best case scenario for an FDA response. There were only 2 possible outcomes here: 1) FDA says Rezolute needs to conduct a new cHI study (end of the road since RZLT has already said they won’t do that) 2) FDA opens the door for more in depth evaluation This is a big win, but the market doesn’t seem to agree.

$RZLT Newbie bear? I just remember the paperwork, Cantor helped RZLT sell 11.25M shares + 3.75M prefunded warrants in 2024... you see "Overweight"? I remember dilution 😉

$RZLT Finally. So we know that tumor HI is basically a slam dunk (if we didn't already), but say worst case scenario, there is no path forward with cHI, will FDA really grant an approval in tumor HI based on a single, 16 patient study?! If they do, you know it's going to be used off label for cHI. Quite the complicated situation here...

$RZLT 🏥 Rezolute, Inc. announced completion of enrollment in the open-label Phase 3 upLIFT registrational study of ersodetug in tumor hyperinsulinism, with topline results expected mid-December 2026. Prioritized by relevance

$RZLT Price: $4.32 Volume: Above average Catalyst: Traders are reacting to updates on RZLT’s pipeline progress and potential partnership/data readouts. Resistance: $4.75 Support: $3.90 Bull case: A move through $4.75 on strong volume could spark a breakout toward $5.50. Bear case: Failure to hold $3.90 support may send shares back toward $3.50. What I'm watching: Watching for sustained volume above average and a clean close above resistance to confirm strength. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services.

$RZLT this could be five dollars by the end of the week, but it needs to hold these gains which its has been unable to do in the past here comes the true test 

$RZLT You’re STILL mixing two different programs dude. Tumor HI = upLIFT: the filing says 9/16 responders for statistical significance, not 8! And statistical significance IS NOT 98% FDA approval odds. Congenital HI = sunRIZE, today’s pre-BLA recommendation is positive BUT FDA never said “50% approval probability” ... that percentage is yours not theirs. Do the REAL math ! 😉

Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’ $RZLT $XBI https://stocktwits.com/news/equity/markets/rezolute-gets-fda-nod-for-pre-bla-meeting-despite-phase-3-miss-retail-expects-huge-rerating/cZDpxXRRBjG

$RZLT I truly enjoy this site because people share their knowledge not their animosity 

$RZLT truly surprising this has fallen on a pull back with all the positive information but the market is in death, blind, and dumb mode so spec stocks are truly the leprosy of this market . I try to put it this way so you’re out to dinner you order New York strip, and the waiter goes by for somebody else’s table with lobster and start serving it and you start to think maybe I should’ve ordered the lobster 

Latest company news, October 14, 2026: Rezolute fully enrolled its Phase 3 upLIFT study of ersodetug (16 participants) and expects topline data in mid-December 2026. More details in our $RZLT hub on our site. Not investment advice.

$RZLT popping on FDA pre-BLA news despite a rough Phase 3 Seeing a +11% 1D and +6% 5D move Options flow is weak and IV is through the roof This feels like a high volatility play, not a long term hold Upcoming Phase 3 data for upLIFT could shake things up more It's all about timing and managing risk here, not just picking a side Watch those intraday swings if you're in